PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
36.29%
Revenue growth exceeding 1.5x CRON.TO's 13.16%. David Dodd would verify if faster growth reflects superior business model.
0.32%
Cost increase while CRON.TO reduces costs. John Neff would investigate competitive disadvantage.
57.21%
Gross profit growth below 50% of CRON.TO's 223.20%. Michael Burry would check for structural issues.
-43.53%
Margin decline while CRON.TO shows 185.61% expansion. Joel Greenblatt would examine competitive position.
-13.16%
R&D reduction while CRON.TO shows 0.00% growth. Joel Greenblatt would examine competitive risk.
-3.55%
G&A reduction while CRON.TO shows 56.89% growth. Joel Greenblatt would examine efficiency advantage.
41.98%
Marketing expense growth while CRON.TO reduces spending. John Neff would investigate strategic advantage.
-38.63%
Other expenses reduction while CRON.TO shows 11.28% growth. Joel Greenblatt would examine efficiency.
10.53%
Operating expenses growth less than half of CRON.TO's 40.04%. David Dodd would verify sustainability.
99.84%
Total costs growth while CRON.TO reduces costs. John Neff would investigate differences.
-3.41%
Interest expense reduction while CRON.TO shows 68.18% growth. Joel Greenblatt would examine advantage.
19.37%
D&A growth above 1.5x CRON.TO's 4.56%. Michael Burry would check for excessive investment.
203.35%
EBITDA growth 1.25-1.5x CRON.TO's 152.88%. Bruce Berkowitz would examine sustainability.
114.13%
EBITDA margin growth 50-75% of CRON.TO's 157.87%. Martin Whitman would scrutinize operations.
-181.24%
Operating income decline while CRON.TO shows 122.09% growth. Joel Greenblatt would examine position.
-159.61%
Operating margin decline while CRON.TO shows 119.52% growth. Joel Greenblatt would examine position.
-63.57%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-64.79%
Pre-tax income decline while CRON.TO shows 123.10% growth. Joel Greenblatt would examine position.
-74.17%
Pre-tax margin decline while CRON.TO shows 120.42% growth. Joel Greenblatt would examine position.
-92.27%
Tax expense reduction while CRON.TO shows 70.48% growth. Joel Greenblatt would examine advantage.
-57.90%
Net income decline while CRON.TO shows 167.61% growth. Joel Greenblatt would examine position.
-69.11%
Net margin decline while CRON.TO shows 159.75% growth. Joel Greenblatt would examine position.
-53.60%
EPS decline while CRON.TO shows 159.62% growth. Joel Greenblatt would examine position.
-60.74%
Diluted EPS decline while CRON.TO shows 150.00% growth. Joel Greenblatt would examine position.
0.09%
Share count reduction exceeding 1.5x CRON.TO's 11.76%. David Dodd would verify capital allocation.
0.10%
Diluted share reduction exceeding 1.5x CRON.TO's 34.68%. David Dodd would verify capital allocation.